Achaogen, Inc. Follow-On Offering

Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global Market under the symbol “AKAO.”

Based in South San Francisco, California, Achaogen, Inc. is a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant gram-negative infections.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Jeffrey C. Lau and Leeann Saw. The tax team included partner Rachel D. Kleinberg and associate Samantha Jacoby. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.